Sign In
Buy SRRK
$47.30
-1.70 (-3.46%)
At Close: Jul 31, 2026
Scholar Rock Highlights 2026 Strategic Priorities
07:00am, Monday, 12'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of “Buy” by Brokerages
01:30am, Wednesday, 07'th Jan 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) has been assigned a consensus rating of "Buy" from the sixteen brokerages that are presently covering the firm, Marketbeat reports. On
Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating
11:59pm, Monday, 05'th Jan 2026
I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 05'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:57am, Saturday, 13'th Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Brokerages
01:16am, Saturday, 13'th Dec 2025
Shares of Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) have earned a consensus rating of "Buy" from the sixteen research firms that are covering the stock, MarketBeat reports. One
Scholar Rock Holding Corporation $SRRK Stock Holdings Boosted by Federated Hermes Inc.
03:52am, Friday, 12'th Dec 2025
Federated Hermes Inc. increased its position in Scholar Rock Holding Corporation (NASDAQ: SRRK) by 10,809.9% during the second quarter, according to the company in its most recent 13F filing with the
Scholar Rock Holding Corporation $SRRK Position Cut by Fisher Asset Management LLC
04:40am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC lowered its position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) by 9.7% in the undefined quarter, according to its most recent disclosure with the SEC. Th
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
03:33pm, Wednesday, 03'rd Dec 2025
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
09:34am, Wednesday, 03'rd Dec 2025
New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP's
Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript
02:01pm, Friday, 14'th Nov 2025
Scholar Rock Holding Corporation ( SRRK ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Laura Ekas David Hallal - CEO & Chairman of the Board Akshay Vaishnaw - President of
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Friday, 14'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 12'th Nov 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common
3 Beaten-Down Stocks With Rebound Potential This Earnings Season
08:15am, Wednesday, 12'th Nov 2025
Earnings season often shines a spotlight on well-known mega-caps, but it can also bring opportunities for lesser-known companies to shine. Below are three stocks—each down significantly in 2025—th
Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)
11:28am, Monday, 10'th Nov 2025
Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achiev
